Market Closed -
Nasdaq
21:00:00 26/06/2024 BST
|
5-day change
|
1st Jan Change
|
275.4
USD
|
-1.67%
|
|
+2.83%
|
+19.01%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
1,406
|
1,719
|
1,449
|
5,179
|
4,568
|
5,968
|
-
|
-
|
Enterprise Value (EV)
1 |
966.7
|
1,436
|
1,179
|
4,869
|
4,051
|
5,275
|
5,676
|
5,451
|
P/E ratio
|
-16.7
x
|
-8.49
x
|
-5.79
x
|
-16.8
x
|
-11.6
x
|
-10.1
x
|
-15.6
x
|
70.7
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
-
|
-
|
-
|
-
|
-
|
81.2
x
|
16.4
x
|
6.06
x
|
EV / Revenue
|
-
|
-
|
-
|
-
|
-
|
71.8
x
|
15.6
x
|
5.53
x
|
EV / EBITDA
|
-10.2
x
|
-6.96
x
|
-4.87
x
|
-16.6
x
|
-10.7
x
|
-8.65
x
|
-11.3
x
|
-34.1
x
|
EV / FCF
|
-23.1
x
|
-9.09
x
|
-4.87
x
|
-16.6
x
|
-12.4
x
|
-8.95
x
|
-13.1
x
|
-31.7
x
|
FCF Yield
|
-4.32%
|
-11%
|
-20.6%
|
-6.01%
|
-8.04%
|
-11.2%
|
-7.65%
|
-3.16%
|
Price to Book
|
3.37
x
|
7.18
x
|
7.15
x
|
26.6
x
|
11.3
x
|
11
x
|
58.2
x
|
21
x
|
Nbr of stocks (in thousands)
|
15,429
|
15,466
|
17,097
|
17,842
|
19,743
|
21,312
|
-
|
-
|
Reference price
2 |
91.11
|
111.2
|
84.74
|
290.2
|
231.4
|
280.0
|
280.0
|
280.0
|
Announcement Date
|
26/02/20
|
25/02/21
|
24/02/22
|
23/02/23
|
28/02/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
-
|
73.49
|
364.2
|
985.4
|
EBITDA
1 |
-94.86
|
-206.2
|
-242.1
|
-293.1
|
-380
|
-609.7
|
-502.6
|
-159.8
|
EBIT
1 |
-94.97
|
-206.7
|
-242.5
|
-293.6
|
-380.5
|
-612.3
|
-412.9
|
125.1
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-833.26%
|
-113.38%
|
12.7%
|
Earnings before Tax (EBT)
1 |
-83.95
|
-202.2
|
-241.8
|
-295.4
|
-373.6
|
-598
|
-414.7
|
112
|
Net income
1 |
-83.95
|
-202.2
|
-241.8
|
-295.4
|
-373.6
|
-583
|
-403.2
|
97.71
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-793.29%
|
-110.72%
|
9.92%
|
EPS
2 |
-5.450
|
-13.09
|
-14.63
|
-17.23
|
-19.99
|
-27.68
|
-17.98
|
3.959
|
Free Cash Flow
1 |
-41.8
|
-157.9
|
-242.3
|
-292.5
|
-325.7
|
-589.6
|
-434.3
|
-172.1
|
FCF margin
|
-
|
-
|
-
|
-
|
-
|
-802.25%
|
-119.26%
|
-17.46%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
26/02/20
|
25/02/21
|
24/02/22
|
23/02/23
|
28/02/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
2025 Q2
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
3.882
|
22.65
|
50.56
|
58.65
|
75.13
|
EBITDA
1 |
-
|
-
|
-
|
-
|
-
|
-78.21
|
-
|
-
|
-
|
-151.9
|
-138
|
-134.8
|
-124.4
|
-
|
-
|
EBIT
1 |
-64.6
|
-57.59
|
-70.27
|
-80.41
|
-85.3
|
-78.34
|
-86.45
|
-98.53
|
-117.2
|
-152
|
-163.4
|
-155.1
|
-131.6
|
-139.3
|
-127.3
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-4,208.58%
|
-684.84%
|
-260.37%
|
-237.55%
|
-169.46%
|
Earnings before Tax (EBT)
1 |
-64.55
|
-57.52
|
-70.73
|
-81.2
|
-85.9
|
-76.9
|
-85.8
|
-98.74
|
-112.2
|
-147.5
|
-162.2
|
-154.6
|
-131.7
|
-137.5
|
-126.5
|
Net income
1 |
-64.55
|
-57.52
|
-70.73
|
-81.2
|
-85.9
|
-76.9
|
-85.8
|
-98.74
|
-112.2
|
-147.5
|
-157.7
|
-149.8
|
-128.4
|
-137.5
|
-126.5
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-4,062.25%
|
-661.42%
|
-253.94%
|
-234.51%
|
-168.41%
|
EPS
2 |
-3.790
|
-3.360
|
-4.140
|
-4.750
|
-4.980
|
-4.230
|
-4.690
|
-5.340
|
-5.680
|
-7.380
|
-7.654
|
-7.188
|
-6.084
|
-6.382
|
-5.844
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
24/02/22
|
09/05/22
|
04/08/22
|
03/11/22
|
23/02/23
|
09/05/23
|
08/08/23
|
06/11/23
|
28/02/24
|
07/05/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
439
|
284
|
270
|
309
|
517
|
694
|
292
|
517
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-41.8
|
-158
|
-242
|
-293
|
-326
|
-590
|
-434
|
-172
|
ROE (net income / shareholders' equity)
|
-18.8%
|
-61.6%
|
-111%
|
-
|
-124%
|
-122%
|
-157%
|
-80.4%
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
2 |
27.00
|
15.50
|
11.90
|
10.90
|
20.40
|
25.50
|
4.810
|
13.30
|
Cash Flow per Share
2 |
-
|
-
|
-
|
-
|
-
|
-17.60
|
-14.00
|
-
|
Capex
1 |
0.17
|
0.33
|
0.21
|
0.22
|
1.48
|
2.07
|
2.36
|
2.25
|
Capex / Sales
|
-
|
-
|
-
|
-
|
-
|
2.82%
|
0.65%
|
0.23%
|
Announcement Date
|
26/02/20
|
25/02/21
|
24/02/22
|
23/02/23
|
28/02/24
|
-
|
-
|
-
|
Average target price
365.1
USD Spread / Average Target +30.36% Consensus |
1st Jan change
|
Capi.
|
---|
| +19.01% | 5.97B | | +16.49% | 122B | | +21.73% | 116B | | +22.18% | 27.03B | | -21.81% | 20.36B | | -16.89% | 16.43B | | -18.81% | 15.91B | | -44.74% | 15.6B | | +62.72% | 14.94B | | +3.09% | 13.59B |
Bio Therapeutic Drugs
|